Selection criteria
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews and meta-analyses was applied to the methods of this study. Studies with the following characteristics were considered eligible for this analysis: a) had a randomized controlled design; b) included patients with prior myocardial infarction and VT; c) studies with outcomes stratified by LVEF; d) included patients that were randomized to first line VT ablation or a control group based on medical therapy as an initial therapy; e) patients were followed for an average duration of at least 12 months; f) studies included survival-free from VT/VF and/or rates of appropriate ICD therapies as their endpoints.